CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

Repositioning genes awakens fetal hemoglobin to treat disease. CRISPR editing may change future gene therapy. Researchers ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing ...

Researchers have found a promising new method for gene therapy. They successfully restarted inactive genes by bringing them ...

Baby KJ Muldoon, the first patient to successfully receive personalized CRISPR gene editing therapy has returned home after over 300 days at the hospital.